A B STR A CT A new, autosomally inherited abnormal fibrinogen associated with hypofibrinogenemia has been described in several members of a family. Plasma fibrinogen measured either as thrombin-clottable protein or by immunodiffusion revealed a fibrinogen level ranging between 60 and 90 mg/100 ml. The thrombin time of plasma or purified fibrinogen was prolonged and only partially corrected by the addition of calcium. Purified fibrinogen prolonged the thrombin time of normal plasma. Fibrinopeptide release by thrombin was normal in rate and amount, but fibrin monomer aggregation was grossly disturbed, especially in a high ionic strength medium. We have designated this fibrinogen "fibrinogen Philadelphia." Acrylamide gel electrophoresis of mixtures of ["'I]normal and ['I]abnormal fibrinogens revealed a slight increase in the anodal mobility of fibrinogen Philadelphia. Similarly, DEAEcellulose chromatography showed slightly stronger binding of fibrinogen Philadelphia than normal. To elucidate the mechanism responsible for the low plasma fibrinogen concentration, simultaneous metabolic studies of autologous (patient) and homologous (normal) fibrinogen, labeled with 1'I and 181I, respectively, were performed in two affected subjects. Autologous fibrinogen half-life was short and the fractional catabolic *rate was markedly increased in both family members. In contrast, homologous fibrinogen half-life and fractional catabolic rate were normal. These metabolic studies demonstrate that rapid degradation of fibrinogen This work wvas presented in part at the 64th Annual
INTRODUCTION
Inherited functional abnormalities of fibrinogen have been described in several families . Clinical expression of the defect is variable, ranging from no clinical manifestations (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , to bleeding (9, (12) (13) (14) (15) (16) (17) (18) (19) (20) and even thrombotic episodes (14, 20, 21) . Wound dehiscence also has been reported (1, 3) . The most frequent abnormalities of coagulation tests are prolonged prothrombin and thrombin times and an inhibitory effect of patient plasma or fibrinogen on the thrombin time of normal plasma. The functional defect in these dysfibrinogenemias has been related either to an abnormality in the proteolytic release of fibrinopeptides from fibrinogen by thrombin or to an abnormality in the subsequent aggregation of fibrin monomers. The plasma fibrinogen concentration, when measured by methods based on thrombin-clottable protein, has generally been low (22) , but assay by chemical or immunochemical methods has resulted in normal values in all cases but one (12) .
We have recently had the opportunity to study a family with an abnormal fibrinogen characterized by disturbed fibrin monomer aggregation and a low circulating plasma fibrinogen concentration determined by both biological and immunochemical methods. Radioisotopic studies have demonstrated a much more rapid catabolism of this mutant fibrinogen that the normal species, apparently accounting for the depressed fibrinogen levels found in affected members. These fea-tures differentiate this abnormal fibrinogen from previously described dysfibrinogenemias, and we propose that it be designated "fibrinogen Philadelphia."
METHODS
Blood was collected with plastic syringes into 1/9 vol 0.1 M trisodium citrate and transferred to plastic tubes. After centrifugation for 15 min at 4VC and 2,500 g, the plateletpoor plasma was removed and either tested immediately or quick-frozen in acetone-dry ice and stored at -850C.
Fibrinogen purification. Normal fibrinogen was purified from ACD plasma obtained from healthy Australia antigen negative donors by the method of Kazal, Amsel, Miller, and Tocantins (23) . The abnormal fibrinogen was purified by the same method from ACD plasma obtained from the propositus (J. S.) and her son (D. S.). Normal and D. S. fibrinogens were lyophilized and stored at -850C; J. S. fibrinogen was quick-frozen and stored at the same temperature. The amount of fibrinogen present in the purified materials was measured spectrophotometrically at 280 nm, pH 7.1, by assuming an A'801% of 13.9, the figure obtained by Kazal et al. (23) . When normal fibrinogen is prepared by this technique, the protein is consistently more than 94% clottable.
Coagulation studies. Platelets were counted by the method of Brecher and Cronkite (24) . The bleeding time was determined by the method of Ivy, Nelson, and Bucher (25) . Partial thromboplastin time and prothrombin time were done by standard methods (26) . Plasma prothrombin was assayed by the two-stage technique of Ware and Seegers (27) slightly modified (28) . Factor V was measured by the correction of the prolonged prothrombin time of aged oxalated plasma (29) . Factors VII and X were each measured by the correction of the one-stage prothrombin time of congenitally deficient substrate plasmas. Factor X was also assayed with Diagen substrate plasma' (30) . Factors XII, XI, IX, and VIII activities were measured by the kaolin-activated partial thromboplastin time (31) with artificially depleted plasma (32) for the Factor XI assay and congenitally deficient plasmas (with less than 1%o activity) for the others. Factor XIII activity was estimated by incubating a 1-ml clot with 5 ml of 5 M urea and observing for dissolution at 24 h. The euglobulin lysis time was performed by the method of Blix and Aas (33) . This test was repeated after the propositus' plasma was enriched with her own purified fibrinogen to bring the plasma fibrinogen concentration within the normal range. The presence in plasma of fibrin monomer complexes was tested by the serial dilution protamine sulfate test (34) . Serum fibrinogen-fibrin-related antigens were measured by a latex agglutination test (35) . The thrombin clotting time was performed by adding to 0.1 ml of plasma 0.2 ml of imidazole buffered saline (0.15 M NaCl, 0.045 M imidazole, pH 7.4) and 0.1 ml of bovine thrombin (10 U/ml imidazole buffered saline) . In some experiments the imidazole buffered saline contained 0.01 M CaCl2. Thrombin clotting times were also done on normal and propositus purified fibrinogen. Fibrinogen was dissolved in 0.055 M sodium citrate, pH 7.4, at a concentration of 1.30 mg/ml. 0.1 ml of this solution was mixed with 0.2 ml of imidazole buffered saline and 0.1 ml of bovine thrombin (10 U/ml imidazole buffered saline). Inhibition of the 'Diagnostic Reagents, Ltd., Thame, Oxon, England.
2'Upjohn Co., Kalamazoo, Mich. thrombin time of normal plasma was tested by mixing normal plasma with various amounts of normal or propositus plasma or normal or propositus purified fibrinogen. The purified fibrinogen solutions had equivalent concentrations (1.3 mg/ml) so that the total amount of fibrinogen was constant in the test system. Reptilase times were performed with venom from Bothrops atroxrs diluted with distilled water. The system was identical to the one described for the thrombin time method, except that 0.1 ml (20 jug/ml) of Reptilase was substituted for thrombin.
Fibrinogen concentration was determined by thrombin clottability with the method of Ellis and Stransky (36) , ammonium sulphate precipitation (37) , and quantitative immunodiffusion, by using commercial antibody-containing agar plates.'
Fibrinopeptide release during coagulation was investigated by a method similar to that described by Gralnick, Givelber, Shainoff, and Finlayson (17) . Lyophilized fibrinogen, containing sodium citrate, was dissolved in distilled water to a concentration of 3.5 mg/ml fibrinogen and 0.055 M citrate. 0.5-ml aliquots of this fibrinogen solution (1.75 mg) were added to a series of tubes containing 0.05 ml of bovine thrombin (2.5 U). At intervals 0.5 ml of 4% acetic acid was added to each tube. After the clot had dissolved, the mixture was treated with 0.05 ml 100% trichloroacetic acid (TCA).5 30 min later the samples were centrifuged, and the protein present in the supernate was measured by the Folin-Lowry method (38) , as modified by Gralnick et al. (17) . Fibrinopeptides were also measured as the amount of TCA-soluble arginine present in the supernate (17) .
Fibrin monomer aggregation studies were done by several methods. One was similar to the procedure described by von Felten, Frick, and Straub (39) . 100 ml of plasma, containing 0.5% Na EDTA and 25,000 U Trasylol 6 
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Cleveland (3). The low fibrinogen level in D. S. plasma was increased to normal by the addition of his own purified fibrinogen. In this experiment 0.5 ml of normal or D. S. l)lasmTa was mixed with 1 ml of barbital-sodium acetate buffer, pH 2.6, bringing the mixture to a final pH of 5.2. Human thrombin (100 U) was added to the acidified plasma, and the mixture was incubated at 37°C. At timed intervals 0.2 ml of barbital-sodium acetate buffer, pH 9.6, containing 15 U heparin, was added to 0.2 ml of the incubation mixture (final pH 7.2), and the clotting time was recorded. To examine the influence of D. S. fibrin monomers on the aggregation of normal monomers, 0.25 ml of normal plasma was mixed with 0.25 ml of D. S. plasma, and the same procedure was followed.
Electrophoretic and chroniatographic studies. Immunoelectrophoretic studies were performed in 1%o agarose at pH 8.6 and pH 8.2 in barbital buffers with commercial rabbit antihuman fibrinogen antiserum.4 Polyacrylamide gel electrophoresis was done by the method of Davis (40), with 7.5% gels and pH 8.5 Tris-glycine or pH 7.5 barbitalHCl buffers, and also in sodium dodecylsulfate-dithiothreitol (SDS-DTT) as described by McDonagh, Messel, McDonagh, Murano, and Blomback (41) . Densitometry was performed on the stained gels with a Gilford gel-scanner.7
In some experiments ["311]fibrinogen purified from normal plasma and [I251]fibrinogen purified from the propositus or her son's plasma were mixed and run in the gel. After electrophoresis the gels were stained with Coomassie blue and cut into 2-mm segments. The gel segments were placed inside glass tubes, and the radioactivity present in each gel segment was counted in a two-channel Nuclear-Chicago apart, and fibrinogens were labeled immediately before injection. Just before injection, the labeled proteins wvere passed through a G2, 0.22-gm Millipore filter.12 20-25 ,uCi of each protein were injected through separate syringes, and 5-ml blood samples were drawn 15 min and 4 h later and once daily for another 6 days. In all samples, more than 95%o of the plasma radioactivity was clottable. Catabolic and synthetic rates of fibrinogen were calculated from the plasma radioactivity disappearance curves by the method of Matthews (46) . Fractional catabolic rates were also calculated from the 24-h urinary excretion of radioactivity (47) . 24 h after the labeled fibrinogens were injected, 5 ml of plasma from each subject was filtered through a 2. 
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Reptilase times of propositus (J. S.) plasma is shown in Fig. 2 . The prolonged thrombin time of propositus plasma shortened considerably after the addition of calcium but still remained longer than the thrombin time of normal plasma in a calcium-free system. The Reptilase time of propositus plasma was markedly prolonged Fig. 4 . Both the rate and final amount of fibrinopepticle released are entirely normal. Identical results were obtained with the Folin-Lowry method.
Fibrin monomer aggregation, on the other hand, was grossly abnormal (Fig. 5) . When normal fibrin monomers are allowed to aggregate in a high (0.2) ionic strength medium, there is an initial delay in fibrin formation, followed by a rapid rise in absorbance which reaches a plateau after 20 min of incubation. D. S. fibrin monomers did not show any aggregation at this ionic strength. In a low (0.05) ionic strength buffer, both normal and D. S. fibrin monomers initiated aggregation immediately, although D. S. still showed decreased total aggregation when compared with normal.
Fibrin monomer aggregation was also studied in plasma (Fig. 6) in the same electrophoretic system, D. S. fibrinogen consistently migrated 2-4 mm more anodally than normal (Fig. 7) . In SDS-DTT polyacrylamide gels no differences were noted between the mobilities of Aa, Bfi, and -v chains of J. S. and normal fibrinogen. Densitometric tracings (Fig. 8) confirm this observation and demonstrate, in addition, the presence of intact Aa chains in J. S. fibrinogen as judged by ratios of staining intensity of Aa, Bfi, and ' bands.
Simultaneous gradient elution chromatography on DEAE-cellulose of normal [JI] fibrinogen mixed with D. S. or J. S. fibrinogen revealed some differences. Both normal and abnormal fibrinogens eluted in two major peaks, as previously described by Finlayson and Mosesson (42) . However, the abnormal fibrinogen first peak eluted two tubes later than the normal fibrinogen first peak (Fig. 9 A) . A similar difference may be present in the second peak. These differences cannot be ascribed to the iodination procedure itself since labeled and nonlabeled fibrinogens eluted at the same position in this gradient system (Fig. 9 B) . Metabolic studies. The results of autologous and homologous fibrinogen metabolic studies performed in the propositus (J. S.) and her son (D. S.) are depicted in Fig. 10 and Table II . The normal fibrinogen metabolic data given in Table II Takeda (48) and the mean values calculated from the data of several investigators (49) . In both family members normal fibrinogen showed a normal half-life and fractional catabolic rate. In contrast the subjects' own fibrinogen had a shortened half-life-1.91 days in.D. S. and 1.58 days in J. S. Fractional catabolic rates calculated either from the plasma radioactivity disappearance curves or from urinary radioactivity excretion were markedly increased in both family members-49% of the intravascular pool per day in D. -S. and 91% in J. S. In all cases the fraction of plasma radioactivity excreted in the urine was lower in the first 24 h of the study than in any subsequent 24-h period, suggesting the absence of significant denaturation in the injected fibrinogen preparations.
When plasma samples were gel-filtered on Sepharose (12) , many other dysfibrinogenemias have been described. Although functional and physicochemical studies have established the distinctness of many of the abnormal fibrinogens, a specific amino acid substitution has been found only in fibrinogen Detroit (50) . The distinctive features of these dysfibrinogenemias have been recently reviewed (51, 52) . The functional clotting defect of an abnormal fibrinogen may be due to (a) an altered reactivity to the proteolytic action of thrombin, (b) a disturbance in the aggregation of fibrin monomers, or (c) a diminished ability to form covalently linked fibrin polymers under the influence of Factor XIII. In some cases a combination of the first two mechanisms has been reported (51, 52) . Fibrinogen Philadelphia exhibits a low reactivity to thrombin and Reptilase that is partially corrected by the addition of calcium. The shortening of thrombin and Reptilase times under the influence of calcium probably represents an acceleration of fibrin monomer aggregation rather than of the proteolvtic action of thrombin, as has previously been demonstrated for normal fibrinogen (53, 54) and fibrinogen Zurich (39) . An unusual aspect of the behavior of fibrinogen Philadelphia, however, is the progressive lengthening of thrombin times with increasing concentrations of thrombin. There is no explanation at present for this behavior. Fibrinogen Philadelphia releases a normal total amount of fibrinopeptide at a normal rate when exposed to thrombin. The whole blood clot is not soluble in urea, indicating grossly normal covalent cross-linking by Factor XIII. The abnormality responsible for the coagulation defect is a delay in fibrin monomer aggregation. This abnormality is still more evident when the monomers are allowed to aggregate in a medium of high ionic strength, as previously described with another genetically abnormal fibrinogen (39) . The inhibiting effect of high ionic strength is not unique to hereditary dysfibrinogenemias, however, since fetal fibrinogen (55) and an abnormal fibrinogen described in a patient with primary hepatoma (56) behave in a similar fashion. The lack of aggregation of fibrin monomers in a high ionic strength medium is suggestive of a defect in the end-to-end aggregation of fibrin monomers (57) (58) (59) (5) and fibrinogen Metz, which showed a slight increase in the anodal migration of the Aa-chain (9) . The delayed elution of fibrinogen Philadelphia on DEAE-cellulose is similar to that of fibrinogens Nancy (10), Paris II (4), and Baltimore (60) . In the latter two fibrinogens Mosesson observed heterogeneity of the major peak on DEAE-cellulose, whereas the first peak of fibrinogen Philadelphia is symmetrical. The slight abnormalities of fibrinogen Philadelphia in polyacrylamide gels and DEAE-cellulose are probably significant since they can be demonstrated in experiments involving mixtures of normal and abnormal fibrinogens. Fibrinogen Philadelphia's increased anodal migration and binding to DEAEcellulose are suggestive of an increase of negative charge on the molecule.
In some dysfibrinogenemic families the presence of both normal and abnormal fibrinogens was demonstrated by immunoelectrophoresis, acrylamide gel electrophoresis, DEAE-cellulose chromatography, or coagulation studies (5) . Fibrinogen Philadelphia showed no heterogeneity in any of these systems so that the presence of normal fibrinogen could not be demonstrated.
An unusual feature of fibrinogen Philadelphia, which serves to distinguish it from all of the previously reported dysfibrinogenemias except fibrinogen Parma (12) (65, 66) . The normal euglobulin lysis times, absence of fibrinogen-fibrin degradation products, the negative protamine sulfate dilution test, and particularly the homologous fibrinogen turnover studies in these subjects make such possibilities unlikely. Moreover, the disparity between the abnormal autologous and normal homologous fibrinogen catabolic rates clearly demonstrates that the rapid degradation of fibrinogen Philadelphia is due to an intrinsic molecular defect. The decreased fibrinogen levels and intravascular pools in J. S. and D. S. probably play no part in the observed findings, since it has been shown that fibrinogen catabolism is independent of both fibrinogen level and the size of intra-and extravascular fibrinogen pools (67) (68) (69) .
The possibility still exists that the abnormal fibrinogen in this family shows increased sensitivity to plasmin action and that their purified fibrinogen therefore represents early products of plasmin digestion. Such a mechanism might account for faster than normal catabolism. However, the presence of intact Aa chains in fibrinogen Philadelphia seems to rule out this possibility. Furthermore, fragment X and fractions 1-8 and 1-9, the earliest plasmin degradation products of fibrinogen, have very different properties than fibrinogen Philadelphia on acrylamide gel electrophoresis and DEAE-cellulose chromatography (70) .
The mechanisms involved in plasma protein degradation are poorly understood. The catabolism of most glycoproteins seems governed in part, at least, by their carbohydrate content, since removal of terminal sialic acid residues generally results in a shortened half-life (71) . We are -presently studying the possibility that fibrinogen Philadelphia differs from normal in its carbohydrate structure. Actual catabolism of plasma proteins seems to occur in, or in close relation to, the intravascular space. In the particular cases of fibrinogen, limited proteolytic degradation within the intravascular compartment, perhaps partly via the action of thrombin and the fibrinolytic system (72) (73) (74) , may play a significant role. However, it seems likely that fibrinogen and its degradation products undergo further major intracellular proteolysis during their transit from the intravascular to the extravascular spaces (69) .
Genetic hypoproteinemias may be associated with normal or rapid catabolism of the protein in question. Thus, patients with myotonic dystrophy and hypogammaglobtilinemia catabolize homologous IgG rapidly (75, 76) . However, their own IgG has a normal survival in normal recipients, indicating an abnormality of the catabolic apparatus rather than the IgG itself. Hypercatabolismn of the C3 component of complement has been reported in two different genetic disorders (77, 78) leading to low values of C3. In both cases homologous C3 is metabolized rapidly by affected individuals, suggesting that the catabolic defect is extrinsic to the C3 molecule. Yet another mechanism for hypercatabolism is illustrated by the finding of low levels of Clq in patients with hypogammaglobulinemia (79) . The hypercatabolism and increased extravascular distribution observed seem related to the unavailability for interaction with this complement component of normal quantities of specific IgG subtypes. Fibrinogen Bethesda II seems another example of hypercatabolism associated with a defect extrinsic to the protein in question, since both homologous and autologous fibrinogen are metabolized rapidly (6) . The Our data indicate that fibrinogen Philadelphia is altered both in its biologic activity and in its metabolic properties. Whether the defective polymerization and the rapid catabolism are due to the the same mutation is not known at present. In any case, fibrinogen Philadelphia appears to be the first example of a hereditary plasma protein defect associated with abnormal catabolism. In view of our incomplete understanding of the catabolism of plasma proteins, this family affords a unique opportunity to investigate some of the factors governing this process.
